Insulin-like growth factor binding protein 5 enhances survival of LX2 human hepatic stellate cells

Fibrogenesis and Tissue Repair

Volumn 3, Issue 1, 2010, Pages

  Sokolović, Aleksandar ^a   Sokolović, Milka ^a   Boers, Willem ^a   Elferink, Ronald P O ^a   Bosma, Piter J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INTERSTITIAL COLLAGENASE; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN C; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

APOPTOSIS; ARTICLE; CELL STRAIN; CELL STRAIN LX2; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; LIVER FIBROSIS; MYOFIBROBLAST; PROTEIN ANALYSIS; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; STELLATE CELL;

EID: 79952042322     PISSN: None     EISSN: 17551536     Source Type: Journal    
DOI: 10.1186/1755-1536-3-3     Document Type: Article

References (55)

1. Friedman SL. Liver fibrosis -- from bench to bedside. J Hepatol 2003, 38(Suppl 1):S38-S53. 10.1016/S0168-8278(02)00429-4, 12591185.
2. Blomhoff R, Wake K. Perisinusoidal stellate cells of the liver: important roles in retinol metabolism and fibrosis 6. FASEB J 1991, 5:271-277.
3. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008, 214:199-210. 10.1002/path.2277, 2693329, 18161745.
4. Ikeda K, Wakahara T, Wang YQ, Kadoya H, Kawada N, Kaneda K. In vitro migratory potential of rat quiescent hepatic stellate cells and its augmentation by cell activation. Hepatology 1999, 29:1760-1767. 10.1002/hep.510290640, 10347119.
5. Kinnman N, Hultcrantz R, Barbu V, Rey C, Wendum D, Poupon R, Housset C. PDGF-mediated chemoattraction of hepatic stellate cells by bile duct segments in cholestatic liver injury. Lab Invest 2000, 80:697-707.
6. Marra F, Romanelli RG, Giannini C, Failli P, Pastacaldi S, Arrighi MC, Pinzani M, Laffi G, Montalto P, Gentilini P. Monocyte chemotactic protein-1 as a chemoattractant for human hepatic stellate cells. Hepatology 1999, 29:140-148. 10.1002/hep.510290107, 9862860.
7. Gressner AM. Liver fibrosis: perspectives in pathobiochemical research and clinical outlook. Eur J Clin Chem Clin Biochem 1991, 29:293-311.
8. Schuppan D, Ruehl M, Somasundaram R, Hahn EG. Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis 2001, 21:351-372. 10.1055/s-2001-17556, 11586465.
9. Boers W, Aarrass S, Linthorst C, Pinzani M, Elferink RO, Bosma P. Transcriptional profiling reveals novel markers of liver fibrogenesis: gremlin and insulin-like growth factor-binding proteins. J Biol Chem 2006, 281:16289-16295. 10.1074/jbc.M600711200, 16606614.
10. Van Nieuwkerk CM, Elferink RP, Groen AK, Ottenhoff R, Tytgat GN, Dingemans KP, Weerman MA, Offerhaus GJ. Effects of Ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glycoprotein gene. Gastroenterology 1996, 111:165-171. 10.1053/gast.1996.v111.pm8698195, 8698195.
11. Gentilini A, Feliers D, Pinzani M, Woodruff K, Abboud S. Characterization and regulation of insulin-like growth factor binding proteins in human hepatic stellate cells. J Cell Physiol 1998, 174:240-250. 10.1002/(SICI)1097-4652(199802)174:2<240::AID-JCP11>3.0.CO;2-G, 9428810.
12. Schneider MR, Wolf E, Hoeflich A, Lahm H. IGF-binding protein-5: flexible player in the IGF system and effector on its own. J Endocrinol 2002, 172:423-440. 10.1677/joe.0.1720423, 11874691.
13. Pilewski JM, Liu L, Henry AC, Knauer AV, Feghali-Bostwick CA. Insulin-like growth factor binding proteins 3 and 5 are overexpressed in idiopathic pulmonary fibrosis and contribute to extracellular matrix deposition. Am J Pathol 2005, 166:399-407. 1602317, 15681824.
14. Clemmons DR, Jones JI, Busby WH, Wright G. Role of insulin-like growth factor binding proteins in modifying IGF actions. Ann N Y Acad Sci 1993, 692:10-21. 10.1111/j.1749-6632.1993.tb26201.x, 7692784.
15. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995, 16:3-34.
16. Twigg SM, Baxter RC. Insulin-like growth factor (IGF)-binding protein 5 forms an alternative ternary complex with IGFs and the acid-labile subunit 1. J Biol Chem 1998, 273:6074-6079. 10.1074/jbc.273.11.6074, 9497324.
17. Scharf JG, Schmitz F, Frystyk J, Skjaerbaek C, Moesus H, Blum WF, Ramadori G, Hartmann H. Insulin-like growth factor-I serum concentrations and patterns of insulin-like growth factor binding proteins in patients with chronic liver disease. J Hepatol 1996, 25:689-699. 10.1016/S0168-8278(96)80240-6, 8938547.
18. Conchillo M, de Knegt RJ, Payeras M, Quiroga J, Sangro B, Herrero JI, Castilla-Cortazar I, Frystyk J, Flyvbjerg A, Yoshizawa C, Jansen PL, Scharschmidt B, Prieto J. Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial. J Hepatol 2005, 43:630-636. 10.1016/j.jhep.2005.03.025, 16024131.
19. Sanz S, Pucilowska JB, Liu S, Rodríguez-Ortigosa CM, Lund PK, Brenner DA, Fuller CR, Simmons JG, Pardo A, Martínez-Chantar ML, Fagin JA, Prieto J. Expression of insulin-like growth factor I by activated hepatic stellate cells reduces fibrogenesis and enhances regeneration after liver injury. Gut 2005, 54:134-141. 10.1136/gut.2003.024505, 1774353, 15591519.
20. Beattie J, Allan GJ, Lochrie JD, Flint DJ. Insulin-like growth factor-binding protein-5 (IGFBP-5): a critical member of the IGF axis. Biochem J 2006, 395:1-19. 10.1042/BJ20060086, 1409685, 16526944.
21. Allen JT, Spiteri MA. Growth factors in idiopathic pulmonary fibrosis: relative roles. Respir Res 2002, 3:13. 10.1186/rr162, 64811, 11806848.
22. Yasuoka H, Jukic DM, Zhou Z, Choi AM, Feghali-Bostwick CA. Insulin-like growth factor binding protein 5 induces skin fibrosis: A novel murine model for dermal fibrosis. Arthritis Rheum 2006, 54:3001-3010. 10.1002/art.22084, 16947625.
23. Yasuoka H, Zhou Z, Pilewski JM, Oury TD, Choi AM, Feghali-Bostwick CA. Insulin-like growth factor-binding protein-5 induces pulmonary fibrosis and triggers mononuclear cellular infiltration. Am J Pathol 2006, 169:1633-1642. 10.2353/ajpath.2006.060501, 1780193, 17071587.
24. Allan GJ, Beattie J, Flint DJ. Epithelial injury induces an innate repair mechanism linked to cellular senescence and fibrosis involving IGF-binding protein-5. J Endocrinol 2008, 199:155-164. 10.1677/JOE-08-0269, 18676497.
25. Xu L, Hui AY, Albanis E, Arthur MJ, O'Byrne SM, Blaner WS, Mukherjee P, Friedman SL, Eng FJ. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut 2005, 54:142-151. 10.1136/gut.2004.042127, 1774377, 15591520.
26. Kim KS, Seu YB, Baek SH, Kim MJ, Kim KJ, Kim JH, Kim JR. Induction of cellular senescence by insulin-like growth factor binding protein-5 through a p53-dependent mechanism. Mol Biol Cell 2007, 18:4543-4552. 10.1091/mbc.E07-03-0280, 2043568, 17804819.
27. Seppen J, Rijnberg M, Cooreman MP, Oude Elferink RP. Lentiviral vectors for efficient transduction of isolated primary quiescent hepatocytes. J Hepatol 2002, 36:459-465. 10.1016/S0168-8278(01)00308-7, 11943415.
28. Ramakers C, Ruijter JM, Deprez RHL, Moorman AFM. Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. Neuroscience Letters 2003, 339:62-66. 10.1016/S0304-3940(02)01423-4, 12618301.
29. Keijzer R, Blommaart PJ, Labruyère WT, Vermeulen JL, Doulabi BZ, Bakker O, Tibboel D, Lamers WH. Expression of thyroid hormone receptors A and B in developing rat tissues; evidence for extensive posttranscriptional regulation. J Mol Endocrinol 2007, 38:523-535. 10.1677/jme.1.02125, 17496154.
30. Johnson SK, Haun RS. Insulin-like growth factor binding protein-5 influences pancreatic cancer cell growth. World J Gastroenterol 2009, 15:3355-3366. 10.3748/wjg.15.3355, 2712896, 19610136.
31. Meadows KA, Holly JM, Stewart CE. Tumor necrosis factor-alpha-induced apoptosis is associated with suppression of insulin-like growth factor binding protein-5 secretion in differentiating murine skeletal myoblasts. J Cell Physiol 2000, 183:330-337. 10.1002/(SICI)1097-4652(200006)183:3<330::AID-JCP5>3.0.CO;2-N, 10797307.
32. Miyake H, Nelson C, Rennie PS, Gleave ME. Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3'-kinase pathway. Endocrinology 2000, 141:2257-2265. 10.1210/en.141.6.2257, 10830316.
33. Perks CM, McCaig C, Holly JM. Differential insulin-like growth factor (IGF)-independent interactions of IGF binding protein-3 and IGF binding protein-5 on apoptosis in human breast cancer cells. Involvement of the mitochondria. J Cell Biochem 2000, 80:248-258. 10.1002/1097-4644(20010201)80:2<248::AID-JCB140>3.0.CO;2-4, 11074596.
34. Hagens WI, Olinga P, Meijer DK, Groothuis GM, Beljaars L, Poelstra K. Gliotoxin non-selectively induces apoptosis in fibrotic and normal livers. Liver Int 2006, 26:232-239. 10.1111/j.1478-3231.2005.01212.x, 16448462.
35. Butt AJ, Firth SM, Baxter RC. The IGF axis and programmed cell death. Immunol Cell Biol 1999, 77:256-262. 10.1046/j.1440-1711.1999.00822.x, 10361258.
36. Flint DJ, Boutinaud M, Tonner E, Wilde CJ, Hurley W, Accorsi PA, Kolb AF, Whitelaw CB, Beattie J, Allan GJ. Insulin-like growth factor binding proteins initiate cell death and extracellular matrix remodeling in the mammary gland. Domest Anim Endocrinol 2005, 29:274-282. 10.1016/j.domaniend.2005.02.021, 15998501.
37. Tonner E, Allan G, Shkreta L, Webster J, Whitelaw CB, Flint DJ. Insulin-like growth factor binding protein-5 (IGFBP-5) potentially regulates programmed cell death and plasminogen activation in the mammary gland. Adv Exp Med Biol 2000, 480:45-53. full_text, 10959408.
38. Lochrie JD, Phillips K, Tonner E, Flint DJ, Allan GJ, Price NC, Beattie J. Insulin-like growth factor binding protein (IGFBP)-5 is upregulated during both differentiation and apoptosis in primary cultures of mouse mammary epithelial cells. J Cell Physiol 2006, 207:471-479. 10.1002/jcp.20587, 16419030.
39. Ning Y, Hoang B, Schuller AG, Cominski TP, Hsu MS, Wood TL, Pintar JE. Delayed mammary gland involution in mice with mutation of the insulin-like growth factor binding protein 5 gene. Endocrinology 2007, 148:2138-2147. 10.1210/en.2006-0041, 17255210.
40. Cobb LJ, Salih DA, Gonzalez I, Tripathi G, Carter EJ, Lovett F, Holding C, Pell JM. Partitioning of IGFBP-5 actions in myogenesis: IGF-independent anti-apoptotic function. J Cell Sci 2004, 117:1737-1746. 10.1242/jcs.01028, 15075235.
41. Perks CM, Bowen S, Gill ZP, Newcomb PV, Holly JM. Differential IGF-independent effects of insulin-like growth factor binding proteins (1-6) on apoptosis of breast epithelial cells. J Cell Biochem 1999, 75:652-664. 10.1002/(SICI)1097-4644(19991215)75:4<652::AID-JCB11>3.0.CO;2-0, 10572248.
42. McCaig C, Perks CM, Holly JM. Intrinsic actions of IGFBP-3 and IGFBP-5 on Hs578T breast cancer epithelial cells: inhibition or accentuation of attachment and survival is dependent upon the presence of fibronectin. J Cell Sci 2002, 115:4293-4303. 10.1242/jcs.00097, 12376561.
43. Hung PS, Kao SY, Liu CJ, Tu HF, Wu CH, Lin SC. Insulin-like growth factor binding protein-5 enhances the migration and differentiation of gingival epithelial cells. J Periodontal Res 2008, 43:673-80. 10.1111/j.1600-0765.2007.01070.x, 18624948.
44. Iredale JP. Hepatic stellate cell behavior during resolution of liver injury. Semin Liver Dis 2001, 21:427-436. 10.1055/s-2001-17557, 11586470.
45. Wang XM, Yu DM, McCaughan GW, Gorrell MD. Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line. Hepatology 2005, 42:935-945. 10.1002/hep.20853, 16175601.
46. Anan A, Baskin-Bey ES, Bronk SF, Werneburg NW, Shah VH, Gores GJ. Proteasome inhibition induces hepatic stellate cell apoptosis. Hepatology 2006, 43:335-344. 10.1002/hep.21036, 16440346.
47. Shi YF, Fong CC, Zhang Q, Cheung PY, Tzang CH, Wu RS, Yang M. Hypoxia induces the activation of human hepatic stellate cells LX-2 through TGF-beta signaling pathway. FEBS Lett 2007, 581:203-210. 10.1016/j.febslet.2006.12.010, 17187782.
48. Umemura A, Itoh Y, Itoh K, Yamaguchi K, Nakajima T, Higashitsuji H, Onoue H, Fukumoto M, Okanoue T, Fujita J. Association of gankyrin protein expression with early clinical stages and insulin-like growth factor-binding protein 5 expression in human hepatocellular carcinoma. Hepatology 2008, 47:493-502. 10.1002/hep.22027, 18161051.
49. Nishino R, Honda M, Yamashita T, Takatori H, Minato H, Zen Y, Sasaki M, Takamura H, Horimoto K, Ohta T, Nakanuma Y, Kaneko S. Identification of novel candidate tumour marker genes for intrahepatic cholangiocarcinoma. J Hepatol 2008, 49:207-216. 10.1016/j.jhep.2008.03.025, 18490072.
50. Mauad TH, van Nieuwkerk CM, Dingemans KP, Smit JJ, Schinkel AH, Notenboom RG, Weerman MA, Verkruisen RP, Groen AK, Oude Elferink RP, et al. Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am J Pathol 1994, 145:1237-1245. 1887434, 7977654.
51. Popov Y, Patsenker E, Fickert P, Trauner M, Schuppan D. Mdr2 (Abcb4)-/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. J Hepatol 2005, 43:1045-1054. 10.1016/j.jhep.2005.06.025, 16223543.
52. Andress DL. Comparison studies of IGFBP-5 binding to osteoblasts and osteoblast-derived extracellular matrix. Prog Growth Factor Res 1995, 6:337-344. 10.1016/0955-2235(95)00008-9, 8817677.
53. Andress DL. Heparin modulates the binding of insulin-like growth factor (IGF) binding protein-5 to a membrane protein in osteoblastic cells. J Biol Chem 1995, 270:28289-28296.
54. Andress DL. Insulin-like growth factor-binding protein-5 (IGFBP-5) stimulates phosphorylation of the IGFBP-5 receptor. Am J Physiol 1998, 274:E744-E750.
55. Krizhanovsky V, Yon M, Dickins RA, Hearn S, Simon J, Miething C, Yee H, Zender L, Lowe SW. Senescence of activated stellate cells limits liver fibrosis. Cell 2008, 134:657-667. 10.1016/j.cell.2008.06.049, 18724938.